JasonLukeMDFACP

PubMed

• Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hem...
  Jason J Luke, Karen Gelmon, Lillian L Siu, Victor Moreno, Jayesh Desai
  Clinical Cancer Research. 2024-12-13
• 2 citations
  Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
  Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin
  Cancer Cell. 2024-11-11
• The emergence of neoadjuvant immune- over BRAF therapy in melanoma.
  Elisa A Rozeman, Jason J Luke
  Cancer. 2024-10-15

Journal Articles

• T Cell–Inflamed Versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection  
  Jason J. Luke, Randy F. Sweis, Clinical Cancer Research
• ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid t...  
  Luke JJ, LoRusso P, Shapiro GI, Krivoshik A, Schuster R, Yamazaki T, Arai Y, Fakhoury A, Dmuchowski C, Infante JR, Cancer Chemother Pharmacol., 1/25/2016
• New Drugs and Treatment Approaches for Advanced Melanoma: Now that we have effective drugs, how should we combine them?  
  Luke JJ, Hodi FS, Ott PA, Skin Cancer Foundation Journal, 1/1/2014
• Chemotherapy in the management of advanced cutaneous malignant melanoma  
  Luke JJ, Schwartz GK, Clin Dermatol, 5/1/2013
• Join now to see all

Abstracts/Posters

• "Molecularly targeted strategies for advanced ocular melanoma"
  Jason J. Luke, MD, CURE OM Scientific Meeting, Orlando, FL, 1/1/2014
• "Key Issues in the Clinical Development of Immunotherapy Combinations"
  Jason J. Luke, MD, Combination Cancer Immunotherapy Conference, The 9th Annual Immunotherapies and Vaccine Summit, Boston, MA, 1/1/2014
• "Uveal melanoma: unique biology and treatment opportunities"
  Jason J. Luke, MD, Beijing international Melanoma Congress, Beijing, People's Republic of China, 1/1/2014
• "Clinical activity of ipilimumab for metastatic uveal melanoma"
  Jason J. Luke, MD, Workshop: Emerging Research in Uveal Melanoma and Implications for Treatment: Current Status and Future Directions, 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, 1/1/2013
• "Drug Development in Melanoma by Molecular and Anatomical Subset"
  Jason J. Luke, MD, Special Seminar-Section of Hematology/Oncology, The University of Chicago Pritzker School of Medicine, Chicago, IL, 1/1/2013
• Join now to see all

Lectures

• A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresec... 
  2019 ASCO Annual Meeting - 6/1/2019
• Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers. 
  2019 ASCO Annual Meeting - 6/1/2019
• Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalize... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Fellows Grand Rounds: "ASCO 2014: Melanoma" 
  1/1/2014
• Medical Grand Rounds: "Immunotherapy in Cancer: From Principles to Practice" 
  Norman, OK - 1/1/2014
• "Best of ASCO 2014: Melanoma" 
  Boston, MA - 1/1/2014
• Grand Rounds: "Evolving Standards of Care for Melanoma and Opportunities for Drug Development" 
  Department of Hematology/Oncology, Columbia University Medical Center, New York, NY - 1/1/2014
• Fellows Grand Round0: "ASCO 2013: Melanoma" 
  1/1/2013
• Medical Grant Rounds: "Updates on standard of care for melanoma and future directions" 
  Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, MA - 1/1/2013
• "Advances in immunotherapy for melanoma with immune check-point blockade" 
  Children's Hospital Boston, Boston, MA - 1/1/2013
• Medical Grand Rounds: "Updates on standard of care for melanoma and future directions" 
  St. Anne's Hospital, Fall River, MA - 1/1/2013
• "Difficult cases and updates on the standard of care for melanoma" 
  Weymouth, M - 1/1/2013
• "Molecularly directed therapy for melanoma: BRAF and beyond" 
  Boston, MA - 1/1/2013
• Join now to see all

Other

• Interview for Helio Hematology/Oncology, "Novel Antibody Targets for Immune-Checkpoint blockade" 
  Jason J. Luke, MD
  http://www.healio.com/hematology-oncology/highlights-from-hot-melanoma-2014/review-highlights-advances-in-immune-checkpoint-blockade-novel-antibody-targets
  1/1/2014
• Interview for OncLive, "Discussion of the Phase III COMBI-d Trial Results" 
  Jason J. Luke, MD
  http://www.onclive.com/conference-coverage/asco-2014/Dr-Luke-on-the-Results-of-the-COMBI-d-Trial
  1/1/2014
• Interview for OncLive, "Discussion of the Giants of Cancer Care Program" 
  Jason J. Luke, MD
  http://giants.onclive.com/news
  1/1/2014